Paul G. Allen Frontiers Group [to 18 Jan 2020]
Hodgkin lymphoma recruits and trains immune cells to help it thrive
January 14, 2020
Study also highlights possible new targets for treatment, how to better tailor cancer therapies for individual patients


BMGF – Gates Foundation [to 18 Jan 2020]
No new digest content identified.


Bill & Melinda Gates Medical Research Institute [to 18 Jan 2020]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.


CARB-X [to 18 Jan 2020]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
CARB-X funds Trellis Bioscience to support the development of a monoclonal antibody designed to disrupt superbugs’ protective coating so that antibiotics can kill them
CARB-X is awarding Trellis Bioscience, of Redwood City, California, USA, up to $3.2 million in non-dilutive funding, with the possibility of $3.8 million more if certain project milestones are met, to develop an innovative monoclonal antibody designed to disrupt the protective biofilm that makes bacteria resistant to antibiotics.


CEPI – Coalition for Epidemic Preparedness Innovations [to 18 Jan 2020]
Latest news
Newly discovered coronavirus in Wuhan China
Our CEO, Richard Hatchett, discusses how the rapid publication of the genetic sequence of the newly discovered beta coronavirus could help speed up the development of diagnostic tests, case…
Blog 17 Jan 2020
[See Milestones above for detail]


Clinton Health Access Initiative, Inc. (CHAI) [to 18 Jan 2020]
News & Press Releases
No new digest content identified.


EDCTP [to 18 Jan 2020]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.


Emory Vaccine Center [to 18 Jan 2020]
No new digest content identified.


European Medicines Agency [to 18 Jan 2020]
News & Press Releases
News: Mandatory use of international standard for the reporting of side effects to improve safety of medicines
Last updated: 15/01/2020
At its December 2019 meeting, EMA’s Management Board agreed to the mandatory use of a consistent international format, the ISO ICSR format, for reporting individual cases of suspected side effects in patients across the world. This follows a recommendation from EMA’s safety committee (PRAC) in October 2019. The use of the new international standard will become mandatory as of 30 June 2022 for all reporting to EudraVigilance, the European database of suspected side effects with medicines authorised in the European Economic Area (EEA).

The ISO ICSR standard is based on the ICH E2B(R3) modalities for the reporting of suspected side effects of medicines in individual case safety reports (ICSRs). Compared to the older reporting formats it improves the quality of data collected and increases the ability to search and analyse these data. This will better support regulatory authorities and companies to detect and address safety issues with medicines and therefore protect patients. In addition, the ISO standard strengthens personal data protection in the records of ICSRs collected by regulatory authorities and companies.

A guide , jointly developed by EMA and the Heads of Medicines Agencies (HMA), was published in 2015 to help pharmaceutical companies, sponsors of clinical trials and medicines regulatory authorities in EU Member States prepare for the use of the new standard. The guide specifically defines the electronic transmission process of ICSRs, the format and content of the ICSR, the business rules for report validation, as well as classification and data quality principles. It also assists software providers and IT developers in the development of pharmacovigilance and safety databases…


European Vaccine Initiative [to 18 Jan 2020]
No new digest content identified.


FDA [to 18 Jan 2020]
Press Announcements
No new digest content identified.


Fondation Merieux [to 18 Jan 2020]
News, Events
The Malagasy Ministry of Education and Technical and Vocational training and the Mérieux Foundation sign an agreement to promote good health practices in schools
January 9, 2020 – Anosy, Antananarivo (Madagascar)
Her Excellency, Marie Thérèse Volahaingo, Minister of the Malagasy Ministry of Education and Technical and Vocational Training, and Luciana Rakotoarisoa, Manager of the Mérieux Foundation in Madagascar, have signed a partnership agreement for the distribution of health education kits throughout the country’s schools…


Gavi [to 18 Jan 2020]
No new digest content identified.
GHIT Fund [to 18 Jan 2020]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.


Global Fund [to 18 Jan 2020]
News & Stories
Data Service: Country Coordinating Mechanism Contacts
17 January 2020

Data Explorer: Location Detail Pages
14 January 2020


Hilleman Laboratories [to 18 Jan 2020]
Hilleman Laboratories Expands into Maternal and Child Health; Plans to Develop a Novel Vaccine Against Group B Streptococcus
16th January 2020, New Delhi: In a bid to strengthen its vaccine portfolio and expand into areas of unmet need, Hilleman Laboratories, a global research and development organization focused on delivering high-impact and affordable vaccines, announced today about plans to venture into the area of maternal and child health.

In this regard, Hilleman Labs is undertaking research and development of an effective and affordable vaccine against Group B Streptococcus to add a positive impact to women and children living in low middle-income countries.

Streptococcus agalactiae or group B streptococcus (GBS) is a leading cause of serious neonatal infections including septicaemia, pneumonia and less frequently meningitis, and urinary tract infections, chorioamnionitis, endometritis and bacteremia in women. GBS is an opportunistic commensal constituting a part of the intestinal and vaginal physiologic flora in almost 25% of healthy adult women. Maternal colonization is the principal route of GBS transmission. GBS converts from the asymptomatic mucosal carriage state to a major bacterial pathogen causing severe invasive infections…

Dr Davinder Gill, CEO, Hilleman Laboratories, said, “Hilleman Labs has embarked on a project to develop a safe, effective and affordable vaccine against Group B Streptococcus. In this project, we will use our expertise in the conjugate vaccine technology in which we have substantial experience. We will design, assemble and test the vaccine within our R&D centre in India.” We will pay close attention to Group B Streptococcus strains that are prevalent in India and South East Asia. Thereafter, we will partner with a vaccine manufacturing company for further development, manufacture and sale of the vaccine. Since there is currently no approved vaccine for Group B Streptococcus, our initiative is an important one for women and children living in low middle-income countries,” he added…


Human Vaccines Project [to 18 Jan 2020]
Press Releases
No new digest content identified.


IAVI [to 18 Jan 2020]
January 14, 2020
IAVI Makes Available Unique Dataset and Samples from Pioneering HIV/AIDS Study in Africa to Researchers
[See Milestones above for detail]



International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.



International Generic and Biosimilar Medicines Association [IGBA]
No new digest content identified.



No new digest content identified.


IFRC [to 18 Jan 2020]
Selected Press Releases, Announcements
Africa, Democratic Republic of the Congo
DR Congo: Red Cross volunteers attacked during Ebola burial
15 January 2020
[See Ebola above for detail]


IVAC [to 18 Jan 2020]
No new digest content identified.


IVI [to 18 Jan 2020]
Selected IVI News & Announcements
IVI and Sweden renew partnership to accelerate vaccines for global public health
January 13, 2020 – SEOUL, South Korea – The International Vaccine Institute (IVI), a Seoul, Korea-based international organization, announced today that the Swedish International Cooperation Agency (Sida) will continue to support IVI’s mission to accelerate vaccine research and development for global health with a total contribution of SEK 50 million (approximately 5.24 million USD) over the next five years as part of a longstanding partnership between the Swedish government and IVI…
Sweden was one of the first countries to sign the IVI Establishment Agreement in 1997 and started funding IVI in 2002 through Sida. Since IVI’s first research collaboration with the University of Gothenburg and Swedish Biological Laboratories in 2000, Sweden has played an invaluable role in developing IVI’s landmark oral cholera vaccine (OCV), Shanchol, and later, Euvichol and Euvichol Plus, vaccines developed through technology transfer from IVI and prequalified by the WHO. To date, over 42 million doses of these low-cost OCVs have been deployed worldwide…


JEE Alliance [to 18 Jan 2020]
Selected News and Events
No new digest content identified.


MSF/Médecins Sans Frontières [to 18 Jan 2020]
Latest [Selected Announcements]
No new digest content identified.


National Vaccine Program Office – U.S. HHS [to 18 Jan 2020]
NVAC 2020 Meetings
February 13-14, 2020 NVAC Meeting
June 9-10, 2020 NVAC Meeting
September 23-24, 2020 Meeting (Virtual)


NIH [to 18 Jan 2020]
Selected News Releases
Panel identifies need for improved implementation of preventive services and reduced health disparities
January 15, 2020 — Scientists urged to engage stakeholders inside and outside the health care system.


PATH [to 18 Jan 2020]
Selected Announcements
No new digest content identified.


Sabin Vaccine Institute [to 18 Jan 2020]
Statements and Press Releases
No new digest content identified.


UNAIDS [to 18 Jan 2020]
Selected Press Releases/Reports/Statements
No new digest content identified.


UNICEF [to 18 Jan 2020]
Selected Statements, Press Releases, Reports
Libya: Tens of thousands of children at risk amidst violence and chaos of unrelenting conflict
Statement by UNICEF Executive Director Henrietta Fore

Press release
First drone and data academy opens in Africa to improve service delivery for children
NEW YORK/ LILONGWE, 13 January 2020 – The first African Drone and Data Academy (ADDA) opened today in Lilongwe, Malawi, UNICEF announced.
The move is part of efforts to promote the use of drones in programmes and services that will impact the lives of children and young people.
“Humanitarian and development programme delivery in Africa and beyond can benefit significantly from the application of drone technology,” said UNICEF Executive Director Henrietta Fore. “The African Drone and Data Academy will be instrumental in equipping young people with the skills they need to use the technology to benefit children and their communities.”
Building on the work of Africa’s first humanitarian corridor launched in Malawi in 2017, the academy will develop expertise in the use of drones for humanitarian, development and commercial purposes across the continent through a 12-week course. It plans to train approximately 150 students to build and pilot drones by 2021. Funding from UNICEF’s partners will provide free tuition to the first cohort of 26 students from across Africa…

Media Advisory
Countries gather for the Global Forum on Childhood Pneumonia
World’s first conference on childhood pneumonia to take place in Barcelona from Jan 29-31


Vaccination Acceptance Research Network (VARN) [to 18 Jan 2020]
No new digest content identified.


Vaccine Confidence Project [to 18 Jan 2020]
No new digest content identified.


Vaccine Education Center – Children’s Hospital of Philadelphia [to 18 Jan 2020]
No new digest content identified.


Wellcome Trust [to 18 Jan 2020]
Opinion | 15 January 2020
It’s now beyond doubt: we need to reimagine the way research works
by Beth Thompson
The findings of our survey of more than 4,000 researchers expose the stark pressures that many face. But together, we can learn from one another’s good practice and come up with new ways to improve research culture.


The Wistar Institute [to 18 Jan 2020]
No new digest content identified.


World Organisation for Animal Health (OIE) [to 18 Jan 2020]
No new digest content identified.





ARM [Alliance for Regenerative Medicine] [to 18 Jan 2020]
No new digest content identified.


BIO [to 18 Jan 2020]
Press Releases
China Phase I Agreement Represents Important Step Towards Addressing Biotech Issues
Washington, D.C. (January 15, 2020) – BIO President and CEO Jim Greenwood released the following statement today regarding the signing of Phase One of the trade agreement with China: “…“We are currently reviewing the details, but we are pleased to see important commitments for agricultural biotechnology, biopharmaceuticals, and GM microorganisms, in addition to commitments related to forced technology transfer and intellectual property. We look forward to working closely with the Administration to monitor the implementation and enforcement of these provisions…”


DCVMN – Developing Country Vaccine Manufacturers Network [to 18 Jan 2020]
No new digest content identified.


IFPMA [to 18 Jan 2020]
Selected Press Releases, Statements, Publications
No new digest content identified.


PhRMA [to 18 Jan 2020]
Selected Press Releases, Statements
Press Release
ICYMI: 2019 brings innovative medicines to patients
Andrew Powaleny   January 17, 2020
New reports from the U.S. Food and Drug Administration (FDA) show a total of 56 novel new medicines were approved in 2019. Among these, 48 were approved by the Center for Drug Evaluation and Research (CDER) and 8 were approved by the Center for Biologics Evaluation and Research (CBER). While medicine approval numbers vary each year, 2019 saw exciting advancements in drug development. These strong approval figures demonstrate biopharmaceutical companies’ unwavering commitment to developing innovative treatments for patients, offering hope for improved health outcomes…